We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
-11.51%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$101M
AUM Growth
-$17.5M
Cap. Flow
-$4.67M
Cap. Flow %
-4.63%
Top 10 Hldgs %
44.39%
Holding
99
New
23
Increased
11
Reduced
26
Closed
11

Top Buys

Rank Stock Value
1
ADVM
Adverum Biotechnologies
ADVM
+$1.8M
2
EPIX
ESSA Pharma
EPIX
+$1.59M
3
NEOS
Neos Therapeutics, Inc
NEOS
+$1.4M
4
WINT
Windtree Therapeutics Inc
WINT
+$1.28M
5
ABEO icon
Abeona Therapeutics
ABEO
+$965K

Top Sells

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$2.03M
2
EVFM
Evofem Biosciences, Inc. Common Stock
EVFM
+$1.66M
3
ATRC icon
AtriCure
ATRC
+$1.52M
4
DERM
Dermira, Inc.
DERM
+$832K
5
CYNA
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
+$812K

Sector Composition

Rank Sector Weight
1 Healthcare 74.78%
2 Financials 0.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SCYX icon
26
SCYNEXIS
SCYX
$37M
$1.14M 1.13%
1,961
-56
-3% -$34.3K
NVDQ
27
DELISTED
Novadaq Technologies Inc.
NVDQ
$1.06M 1.05%
101,841
– –
DRNA
28
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$1.01M 1.01%
123,500
+36,700
+42% +$424K
ASND icon
29
Ascendis Pharma A/S
ASND
$16.5B
$942K 0.93%
53,241
-40,300
-43% -$785K
SPNC
30
DELISTED
Spectranetics Corp
SPNC
$941K 0.93%
79,812
+40,000
+100% +$716K
ZGNX
31
DELISTED
Zogenix, Inc.
ZGNX
$930K 0.92%
68,900
-37,813
-35% -$682K
JNJ icon
32
Johnson & Johnson
JNJ
$617B
$877K 0.87%
9,400
– –
VTAE
33
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
$780K 0.77%
+70,885
New +$753K
INDP icon
34
Indaptus Therapeutics
INDP
$192M
$756K 0.75%
+60
New +$788K
ABEO icon
35
Abeona Therapeutics
ABEO
$369M
$736K 0.73%
+7,273
New +$965K
ARNA
36
DELISTED
Arena Pharmaceuticals Inc
ARNA
$729K 0.72%
38,160
+19,260
+102% +$654K
QURE icon
37
uniQure
QURE
$2.93B
$716K 0.71%
35,000
-5,000
-13% -$132K
CYNA
38
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
$707K 0.7%
44,824
-50,000
-53% -$812K
AKTX
39
Akari Therapeutics
AKTX
$14M
$633K 0.63%
+33
New +$390K
ELOS
40
DELISTED
Syneron Medical Ltd
ELOS
$615K 0.61%
85,947
-5,000
-5% -$48K
ALDR
41
DELISTED
Alder Biopharmaceuticals
ALDR
$590K 0.59%
+18,000
New +$765K
RGLS
42
DELISTED
Regulus Therapeutics
RGLS
$589K 0.58%
+750
New +$770K
CDNA icon
43
CareDx
CDNA
$1.97B
$567K 0.56%
135,927
-9,700
-7% -$64.1K
CELG
44
DELISTED
Celgene Corp
CELG
$562K 0.56%
+5,200
New +$645K
GILD icon
45
Gilead Sciences
GILD
$163B
$560K 0.56%
+5,700
New +$633K
EXAC
46
DELISTED
Exactech Inc
EXAC
$551K 0.55%
31,636
– –
LPCN icon
47
Lipocine
LPCN
$17.4M
$532K 0.53%
2,647
-2,353
-47% -$544K
DERM
48
DELISTED
Dermira, Inc.
DERM
$525K 0.52%
22,500
-34,236
-60% -$832K
MGNX icon
49
MacroGenics
MGNX
$240M
$514K 0.51%
+24,000
New +$753K
BLUE
50
DELISTED
bluebird bio
BLUE
$513K 0.51%
463
– –
1
2
3 4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $439M AUM 10.15% 1-Year Est. Return
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
CPW
Cove Private Wealth Oyster Bay Cove, New York $440M AUM 27.56% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return

DAFNA Capital Management's Q3 2015 Portfolio in Review

As of Q3 2015, DAFNA Capital Management held 99 positions worth $101M, down 15% from $118M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

DAFNA Capital Management withdrew a net $4.67M in Q3 2015, closing 11 positions and reducing 26 holdings. Its most notable exit was Clovis Oncology, Inc., an estimated $2.03M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 75% of assets, up from 73% a quarter earlier, followed by Financials.

Against the trend, DAFNA Capital Management opened a new position in Adverum Biotechnologies worth $1.16M.

  • DAFNA Capital Management's largest Q3 2015 buy was Adverum Biotechnologies: 14,060 shares worth $1.16M.
  • DAFNA Capital Management added most to Windtree Therapeutics Inc in Q3 2015, an estimated $1.28M increase.
  • DAFNA Capital Management's biggest Q3 2015 reduction was AtriCure, cutting an estimated $1.52M.
  • DAFNA Capital Management fully exited Clovis Oncology, Inc. in Q3 2015, selling an estimated $2.03M.
  • DAFNA Capital Management's ten largest holdings make up 44% of its $101M portfolio in Q3 2015.
  • DAFNA Capital Management opened 23 new positions and closed 11 in Q3 2015.
  • DAFNA Capital Management's portfolio value fell 15% quarter-over-quarter to $101M.

Based on DAFNA Capital Management's 13F filing for Q3 2015, filed 13 Nov 2015.